Gene News and Research

Latest Gene News and Research

New research: Fzd9 receptor can stimulate bone formation

New research shows that the Wnt receptor Frizzled-9 promotes bone formation, providing a potential new target for the treatment of osteoporosis. The study appears online on March 14 in The Journal of Cell Biology.

15 Mar 2011

Scientists identify strategy for targeted molecular therapy in liver cancer

In a research study appearing in the journal Cancer Cell on March 14, scientists from Cold Spring Harbor Laboratory and four other institutions have identified a strategy for targeted molecular therapy in liver cancer, which currently has limited treatment options and one of the worst one-year survival rates of any cancer type.

15 Mar 2011

New animal model helps define molecular processes that lead to PA

Pilocytic astrocytoma is the most common pediatric brain tumor, and there are few medical therapies available to those patients for whom surgery is not curative.

15 Mar 2011

Gamida to distribute Health Robotics' CytoCare, i.v.STATION, i.v.SOFT technologies in Israel

Health Robotics today announced that it recently signed an exclusive distribution agreement for its CytoCare, i.v.STATION, and i.v.SOFT world-leading technologies with Israel-based medical technology leader Gamida MedEquip Ltd.

14 Mar 2011

Researchers discover new gene for Sensenbrenner syndrome

Dutch researchers of the Radboud University Medical Center in Nijmegen found a new gene for Sensenbrenner syndrome (Journal of Medical Genetics, 2011 Mar 4). The mutation adds support to the hypothesis that defects in ciliar transport are the cause of the disease. Project leader Dr. Heleen H. Arts is supported by a Kolff Junior Postdoc Grant of the Dutch Kidney Foundation.

14 Mar 2011

WaferGen Biosystems 2010 revenue exceeds guidance

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, today reported financial results for the three months and year ended December 31, 2010.

14 Mar 2011

New research: Rhodopsin pigment in Drosophila may detect temperature

New research from Mount Sinai School of Medicine has discovered that rhodopsin, a pigment of the retina that is responsible for the first events in the perception of light, may also be involved in temperature sensation. This detection had not been revealed in previous studies.

14 Mar 2011

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

Pharmaceutical R&D productivity is consistently undercounted. Most reports fail to fully count the number of new drugs that reach the market, missing out on billions of dollars of sales generated by R&D investment, an analysis of EvaluatePharma data shows.

14 Mar 2011

ChronTech initiates ChronVac-C DNA vaccine Phase IIb study against HCV

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its partner, ChronTech Pharma AB, has initiated a Phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus, delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

14 Mar 2011

New study: Alcohol-related chronic pancreatitis is lower than other causes

The relative rate of alcohol-related chronic pancreatitis is lower when compared to other causes, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

14 Mar 2011

Peanut allergy has a genetic link: Study

A new study suggests that children with a certain gene defect are more likely to develop a peanut allergy. They studied the effect of changes in the gene filaggrin, which helps the skin block out allergens. They noted what has been seen before – the changes in the gene reduce the effectiveness of the barrier, increasing the risk for eczema and asthma.

14 Mar 2011

Combination therapy may overcome Herceptin-resistant breast cancer

Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

14 Mar 2011

New analytic method suggests tumors grow in punctuated, staccato-like bursts

A new method of analyzing cancerous tumors developed by scientists at Cold Spring Harbor Laboratory suggests that tumors may not evolve gradually, but rather in punctuated or staccato-like bursts.

14 Mar 2011

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced the publication of results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.

11 Mar 2011

New technique may find 'hidden' receptors in nerve cells

Scientists at The Scripps Research Institute and University of Pennsylvania have found a way to uncover potential drug targets that have so far remained hidden from researchers' view.

11 Mar 2011

Genetic variant contributes to higher risk of lung cancer, increases tendency to smoke more

Norwegian researchers have discovered genes that increase not only one's risk of lung cancer, but perhaps one's urge to smoke as well. Now these researchers are working on developing a blood test for lung cancer.

11 Mar 2011

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

The Cancer Immunotherapy Consortium, a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD.

11 Mar 2011

FDA holds Senesco's SNS01-T clinical study due to delay of supplier's DMF updation

Senesco Technologies, Inc., announced today that the U.S. Food and Drug Administration has informed the Company that its planned study in multiple myeloma is on hold until the Drug Master File of one of its suppliers is updated.

11 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

Researchers uncover new disease mechanism in patients with CGD

Infection researchers at Umeå University have uncovered a new disease mechanism in patients with Chronic Granulomatous Disease in an international clinical collaboration with the Children's Hospital in Zurich.

11 Mar 2011